Clinical trial · no report yet · Phase 2
ECLYPse
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- NCT06640166 ↗
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm
- Interventions
- encorafenib + cetuximab + FOLFIRI
- Arms
- encorafenib+cetuximab+FOLFIRI · Experimental
- Enrollment
- 25 (estimated)
- Primary outcomes
- 6-month Progression Free Survival rate
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS with Pierre Fabre Pharma GmbH
- Start
- Jun 3, 2024
- Primary completion
- Dec 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT06640166 · updated Feb 12, 2025